Innovent Biologics Management
Management criteria checks 2/4
Innovent Biologics' CEO is Michael Yu, appointed in Jan 2011, has a tenure of 14.33 years. total yearly compensation is CN¥40.60M, comprised of 7.1% salary and 92.9% bonuses, including company stock and options. directly owns 6.51% of the company’s shares, worth €647.98M. The average tenure of the management team and the board of directors is 1.2 years and 3.8 years respectively.
Key information
Michael Yu
Chief executive officer
CN¥40.6m
Total compensation
| CEO salary percentage | 7.14% |
| CEO tenure | 14.3yrs |
| CEO ownership | 6.5% |
| Management average tenure | 1.2yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | CN¥41m | CN¥3m | -CN¥95m |
| Sep 30 2024 | n/a | n/a | -CN¥688m |
| Jun 30 2024 | n/a | n/a | -CN¥1b |
| Mar 31 2024 | n/a | n/a | -CN¥1b |
| Dec 31 2023 | CN¥36m | CN¥3m | -CN¥1b |
| Sep 30 2023 | n/a | n/a | -CN¥1b |
| Jun 30 2023 | n/a | n/a | -CN¥1b |
| Mar 31 2023 | n/a | n/a | -CN¥2b |
| Dec 31 2022 | CN¥33m | CN¥3m | -CN¥2b |
| Sep 30 2022 | n/a | n/a | -CN¥2b |
| Jun 30 2022 | n/a | n/a | -CN¥3b |
| Mar 31 2022 | n/a | n/a | -CN¥3b |
| Dec 31 2021 | CN¥26m | CN¥3m | -CN¥3b |
| Sep 30 2021 | n/a | n/a | -CN¥2b |
| Jun 30 2021 | n/a | n/a | -CN¥1b |
| Mar 31 2021 | n/a | n/a | -CN¥1b |
| Dec 31 2020 | CN¥105m | CN¥3m | -CN¥998m |
| Sep 30 2020 | n/a | n/a | -CN¥1b |
| Jun 30 2020 | n/a | n/a | -CN¥2b |
| Mar 31 2020 | n/a | n/a | -CN¥2b |
| Dec 31 2019 | CN¥76m | CN¥3m | -CN¥2b |
Compensation vs Market: Michael's total compensation ($USD5.63M) is about average for companies of similar size in the German market ($USD5.20M).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
CEO
Michael Yu (60 yo)
Dr. De-Chao Yu, also known as Michael, Ph.D. Co-Founded Innovent Biologics, Inc. in August 2011 and has been its Chairman and Chief Executive Officer since 2011. He served as its President at Innovent Biol...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.3yrs | CN¥40.60m | 6.51% € 648.0m | |
| Chief People Officer | 5.8yrs | CN¥2.79m | 0.020% € 2.0m | |
| Executive Director & Fund Managing Partner | 1.3yrs | CN¥7.15m | 0.20% € 19.6m | |
| Chief Financial Officer | 1.3yrs | no data | no data | |
| General Counsel | less than a year | no data | no data | |
| Chief Commercial Officer | no data | no data | no data | |
| Senior Vice President | no data | no data | no data | |
| Senior Vice President | 1.3yrs | no data | no data | |
| Global Chief Business Officer | 1.1yrs | no data | no data | |
| Senior Vice President | 1yr | no data | no data | |
| Senior Vice President | less than a year | no data | no data | |
| Senior Vice President | less than a year | no data | no data |
Experienced Management: 6IB's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 14.3yrs | CN¥40.60m | 6.51% € 648.0m | |
| Chief People Officer | 1yr | CN¥2.79m | 0.020% € 2.0m | |
| Executive Director & Fund Managing Partner | no data | CN¥7.15m | 0.20% € 19.6m | |
| Member of CMC Strategic Advisory Board & Independent Non-Executive Director | 9.6yrs | CN¥400.00k | 0.0027% € 273.7k | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data | |
| Independent Non-Executive Director | 6.6yrs | CN¥400.00k | 0.00038% € 37.8k | |
| Member of CMC Strategic Advisory Board | no data | no data | no data | |
| Member of CMC Strategic Advisory Board | no data | no data | no data | |
| Member of CMC Strategic Advisory Board | no data | no data | no data | |
| Lead Independent Non-Executive Director | 1yr | CN¥267.00k | 0.00067% € 66.7k | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data |
Experienced Board: 6IB's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 17:58 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Innovent Biologics, Inc. is covered by 57 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Shun Kei Law | CCB International Securities Limited |
| Zhishun Siu | CCB International Securities Limited |